Trial Profile
A retrospective study investigating efficacy of Enzalutamide treatment in patients with metastatic castration resistant prostate cancer by assessing prostate-specific antigen (PSA) at 4 weeks
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2016
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- 07 Apr 2016 New trial record
- 28 Mar 2016 Results published in the Molecular Diagnosis and Therapy.